Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 4/20 | 0.48 |
| ▸ | CNR1 | P21554 | 1/20 | 0.48 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.41 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | DHODH | Q02127 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | STAT6 | P42226 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29990640 | 1.00 | CNR2 (0.48) | CNR2CNR1GRM4NR1H4MAPT | |
| SCHEMBL2006312 | 0.85 | AKR1C3 (0.47) | GRM4NR1H4MAPTSMN1; SMN2HTT | |
| SCHEMBL5493759 | 0.85 | CNR1 (0.51) | CNR2CNR1MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL25168297 | 0.81 | CNR2 (0.48) | CNR2CNR1SMN1; SMN2 | |
| SCHEMBL29990598 | 0.81 | CNR2 (0.48) | CNR2CNR1MAPTALDH1A1HPGD | |
| SCHEMBL29990602 | 0.81 | CNR2 (0.48) | CNR2CNR1SMN1; SMN2 | |
| SCHEMBL25171663 | 0.81 | CNR2 (0.48) | CNR2CNR1MAPTALDH1A1HPGD | |
| SCHEMBL601528 | 0.81 | CNR2 (0.48) | CNR2CNR1GRM4 | |
| SCHEMBL15383148 | 0.81 | CNR2 (0.48) | CNR2CNR1GRM4MAPTSMN1; SMN2 | |
| SCHEMBL15456896 | 0.81 | ALDH1A1 (0.50) | CNR2CNR1MAPTHTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230140276-A1 | TRICYCLIC COMPOUNDS, PREPARATION METHOD AND MEDICAL USE THEREOF | HEFEI AMVITE PHARMACEUTICAL CO., LTD. (CN) | 2023-05-04 | — | — | US | disclosed |
| CN-115427405-A | Tricyclic compound, preparation method and medical application thereof | 合肥医工医药股份有限公司 | 2022-12-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230140276-A1 | TRICYCLIC COMPOUNDS, PREPARATION METHOD AND MEDICAL USE THEREOF | HNMT, CHRM1, HRH4 | CNR2 42/4885CNR1 40/4885GRM4 414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.